Eli Lilly to buy Point Biopharma for $1.4 billion



Eli Lilly and Company revealed on Tuesday its acquisition of Point Biopharma Global Inc., with the total deal valued at approximately $1.4 billion, equivalent to $12.50 per share.

“We are excite…

About the author:

Get involved!

Fai trading in gruppo!
L'unica Academy di trading completamente gratuita per gli utenti FpMarkets

Comments

Ancora nessun commento